Kyntra Bio (KYNB) Stock Analysis

What Kyntra Bio does

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.

Key metrics

ETFs linked to KYNB

Broad-market and Healthcare sector ETFs an investor holding Kyntra Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KYNB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Kyntra Bio?

Kyntra Bio trades under the ticker KYNB on NASDAQ.

Which exchange is KYNB listed on?

KYNB is listed on NASDAQ.

What sector does Kyntra Bio operate in?

Kyntra Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze KYNB in a portfolio?

PortView shows KYNB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.